Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
| 3.25 | |
| 3.23 | |
| - | |
| 3.3899 | |
| 3.12 | |
| 0.97-4 | |
| 223 M | |
| 70 435 K | |
| 0 | |
| -0.11 | |
| 1.008 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
MIAMI, Feb. 21, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 50th Emerging Growth Conference on February 22, 2023. The Emer...
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has o...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
